Hemodynamic effects of extended prone position sessions in ARDS

Annals of Intensive Care

Table 3 Hemodynamic parameters during prone positioning session

Variables	T₁	T₂	T₃	T₄
HR (min⁻¹)	98 ± 23	99 ± 20^a	96 ± 20	95 ± 21
MAP (mmHg)	76 ± 10	79 ± 12^c	77 ± 12	78 ± 14
CVP (cm H₂O)	13 ± 5	14 ± 5^c	13 ± 5	14 ± 5
CI (L min m⁻²)	3.5 ± 1.3^a	3.4 ± 1.2^a	3.4 ± 1.1^a	3.2 ± 1.1
GEF (%)	21 ± 7	20 ± 7^c	21 ± 8	21 ± 7
EVLWI (mL kg⁻¹ PBW)	13.8 ± 4.4	14.2 ± 4.7^a	13.7 ± 4.7	13.1 ± 4.0
PVPI	2.6 ± 1.0^b	2.5 ± 0.9	2.4 ± 0.9	2.5 ± 0.9
GEDVI (mL m⁻²)	719 ± 193	738 ± 185^a,c	757 ± 209^a,c	714 ± 200
CFI (min⁻¹)	5.0 ± 1.9	4.8 ± 1.8^c	4.8 ± 1.8^c	4.7 ± 1.8^c
PTV (mL)	1163 ± 362^a	1189 ± 359^a	1173 ± 354^a	1116 ± 327
ITTV (mL)	2539 ± 653	2602 ± 638^a,c	2619 ± 664^a,c	2482 ± 655
DO₂ (mL min m⁻²)	416 ± 145	NA	414 ± 139	387 ± 126^b,c
Vasopressor dose* (µg kg min⁻¹)	0.92 ± 1.66	0.92 ± 2.04	0.84 ± 1.67^c	0.88 ± 1.76^c
Dobutamine dose** (µg kg min⁻¹)	2.6 ± 6.0	2.6 ± 5.8	2.8 ± 6.1	3.0 ± 6.2
Volume of fluid challenge since preceding time point*** (mL)	NA	158 ± 519	224 ± 566	123 ± 340

Values are mean ± standard deviation. All statistical tests are performed after adjustment for volume of fluid challenges since preceding time point, vasopressor and dobutamine dose unless specifically stated
CI, cardiac index; CFI, cardiac function index; CVP, central venous pressure; DO₂, oxygen delivery; EVLWI, extravascular lung water index; GEDVI, global end-diastolic volume index; GEF, global ejection fraction; HR, heart rate; ITTV, intrathoracic thermal volume; MAP, mean arterial pressure; NA, not available; PBW, predicted body weight; PTV, pulmonary thermal volume; PVPI, pulmonary vascular permeability index; T₁, before prone position, T₂, beginning of prone position session; T₃, end of prone position session; T₄, after prone position session
^ap < 0.05 versus T₄; ^b p < 0.05 versus T₃; ^c p < 0.05 versus T₁
* Adjustment for volume of fluid challenges since preceding time point and dobutamine dose only; ** adjustment for volume of fluid challenges since preceding time point and vasopressor dose only; *** not tested for statistical significance